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Abstract 
Objectives: To evaluate the association between late gadolinium enhancement (LGE) at 
cardiac magnetic resonance (CMR) and ventricular arrhythmias (VA) or sudden cardiac death 
(SCD) in patients with dilated cardiomyopathy (DCM).  
Background: Risk stratification for SCD in DCM needs to be improved.  
Methods: Systematic review and metaanalysis. Systematic search in PubMed and Ovid. 
Inclusion of observational studies that analyzed the arrhythmic endpoint (sustained VA, 
appropriate ICD therapies or SCD) in patients with DCM, stratified by the presence or 
absence of LGE. 
Results: 29 studies were included, accounting for 2948 patients. The studies covered a wide 
spectrum of DCM, with a mean left ventricular ejection fraction (LVEF) between 20% and 
43%. LGE was significantly associated with the arrhythmic endpoint both in the overall 
population (OR 4.3, p<0.001) and when including only those studies that performed 
multivariate analysis (HR 6.7, p<0.001). The association between LGE and the arrhythmic 
endpoint remained significant among studies with mean LVEF >35% (OR 5.2, p<0.001) and 
was maximal in studies that included only patients with primary prevention ICD (OR 7.8, 
p=0.008).  
Conclusions: Across a wide spectrum of DCM patients, LGE is strongly and independently 
associated with VA or SCD. LGE could be a powerful tool to improve risk stratification for 
SCD in DCM. These results raise two major questions to be addressed by future studies: 
whether patients with LGE could benefit from a primary prevention ICD irrespective of their 
LVEF, while patients without LGE might not need a preventive ICD despite having severe 
left ventricular dysfunction. 
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Introduction 
Risk stratification for sudden cardiac death (SCD) among patients with dilated 
cardiomyopathy (DCM) remains inadequate, causing on-going clinical challenges in the 
appropriate identification of candidates for primary prevention implantable cardioverter 
defibrillator (ICD).  
Left ventricular ejection fraction (LVEF) continues to be employed as the main 
criterion to select patients for primary prevention ICD. However, LVEF has low sensitivity 
and low specificity for prediction of SCD.w1 Indeed, only about 20% of patients with DCM 
who have an ICD for primary prevention subsequently receive appropriate therapies from the 
device during follow-up.w2 Recently, the DANISH trial has questioned the benefit of primary 
prevention ICD in non ischemic heart failure.w3 
Myocardial scar is the major substrate for ventricular arrhythmias (VA)w4 but not all 
patients with DCM have an identifiable  scar. Late gadolinium enhancement (LGE) at cardiac 
magnetic resonance (CMR) can detect areas of localised myocardial fibrosis.w5 Several 
studies have analyzed the association between LGE and outcomes, including VA or SCD, in 
DCM. However, with regard to arrhythmic events, results have varied and most of the reports 
were single-center studies including a relatively small number of patients.  
Therefore, we considered it appropriate to perform a metaanalysis that specifically 
addressed the association between LGE and SCD or VA in patients with DCM.  
Methods 
The study was performed in accordance with the PRISMA statement.w6 
Search strategy 
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A systematic search was performed by two investigators in PubMed and Ovid using 
the following keywords: late gadolinium enhancement OR delayed gadolinium enhancement 
OR magnetic resonance AND cardiomyopathy OR arrhythmias OR ventricular tachycardia 
OR ventricular fibrillation OR sudden death OR sudden cardiac death. No language 
restrictions were applied. The search was finalized in August 2015. Abstracts from 2015 
Europace and Heart Rhythm Congresses were also screened for the same keywords, to avoid 
missing studies not yet published in journals. To ensure literature saturation, the reference 
lists of included reports and relevant reviews were also scanned.  
Eligibility criteria, outcomes, selection process and data collection process.  
Observational cohort studies, both prospective and retrospective, were included in the 
metaanalysis if they reported rate of arrhythmic events in adult patients (>18 years old) with 
DCM and provided information about the presence or absence of LGE. Sudden cardiac death, 
ventricular fibrillation, sustained ventricular tachycardia (VT) and appropriate ICD therapies 
were considered as arrhythmic events and represent the main outcome of this metaanalysis. 
Any pattern of non-ischemic LGE was accounted for to define the presence or absence of 
LGE. Only studies that specified the exclusion of significant coronary artery disease in their 
DCM population were included in this analysis.  
Citations initially selected by systematic search were first retrieved as a title and 
abstract and preliminarily screened. Potentially suitable citations were then retrieved as full 
text manuscripts and assessed for compliance to inclusion criteria. The reasons for excluding 
studies were recorded. The search and screening were performed by two independent 
investigators.  
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When the population of the study also included cardiomyopathies other than DCM, 
only DCM patients were considered for the present metaanalysis. For studies where ICD 
therapies were the only arrhythmic end-point analysed and not all patients of the study had 
undergone ICD implantation, only patients with an ICD were included in the metaanalysis. 
Raw data concerning the number of patients with and without arrhythmic events, 
stratified by the presence or absence of LGE were extracted from original reports or obtained 
by contacting the corresponding author directly. Moreover, data on LVEF, percentages of 
patients undergoing ICD implantation, BNP levels and NYHA class were recorded if 
available.  
Quality assessment 
The risk of bias within individual studies was evaluated according to the established 
methods of the Cochrane collaboration.w7 Moreover, given the observational nature of the 
reports, further quality assessment was performed using the Newcastle-Ottawa Quality 
Assessment Scale for Cohort Studies.w8 
Statistical analysis 
Continuous variables are presented as means and standard deviation (SD) or medians 
and interquartile range (IQR); categorical variables as numbers and percentages. 
Binary arrhythmic outcomes from individual studies were first combined with a fixed-
effect model, leading to estimation of pooled odds ratio (OR), pooled hazard ratio (HR), risk 
or rate difference, all of them with 95% confidence intervals (CI). Differences were 
considered statistically significant at the 2-sided p<0.05 level. If a significant heterogeneity 
was observed, a random-effect model was used. In the presence of studies with zero 
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arrhythmic events in one of the two groups of the study, an empirical continuity correctionw9 
was applied to calculate the OR.  
Heterogeneity between studies was assessed with the X2 homogeneity test. 
Heterogeneity was considered significant if the p value was <0.1. Inconsistency was 
calculated with the I2 test which describes the percentage of variability in effect estimates that 
is due to heterogeneity between studies. I2 values of 25%, 50% and 75% correspond to mild, 
moderate and severe heterogeneity effect, respectively. The Tau2 parameter, that expresses 
inter-studies variability, was also reported.  
Publication bias was evaluated using Egger testw10 and Peters testw11 and was 
significant if p<0.1. Since publication bias is influenced by sample size, we performed the 
evaluation of publication bias both in the entire group of studies and, selectively, only in 
those reports that had their entire population taken into account in the metaanalysis.   
All analysis were performed with the STATA RELEASE 12 software (StataCorp LP, 
College Station, Texas, USA).   
Results 
Search results and study selection 
The search allowed the identification of 2660 citations. After the screening process, 
53 full text articles were carefully assessed. Of these, 21 were excluded because they did not 
meet inclusion criteria. Three were excluded1-3 because their data were included in more 
recent publications.4-6 A total of 29 studies were finally included in the metaanalysis (Figure 
1).4-32 
Study quality and risk of bias within studies 
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The assessment of study quality using the Cochrane collaboration method showed 
that, given the observational nature of all studies, the main bias that could not be ruled out 
was selection bias; attrition bias, related to loss of patients during follow-up, was present just 
in few studies (Table 1). 
The Newcastle Ottawa scale pointed out that in many cases comparability of the study 
groups was not ensured on the basis of study design or analysis, due to the observational 
nature of all studies and the lack of multivariate analysis for the arrhythmic endpoint in many 
of them (Table 1 supplementary material); moreover, the majority of studies did not 
demonstrate that the outcome of interest was not already present at the beginning of the 
study, i.e. previous arrhythmic events were not listed as exclusion criteria. Apart from these 
limitations, most of the reports fulfilled all other criteria.  
Study characteristics 
A total of 2948 patients from 29 studies were included in the metaanalysis. DCM was 
usually defined as a reduction in LVEF in the absence of significant coronary artery disease, 
significant valve disease, hypertensive heart disease, infiltrative heart diseases and 
hypertrophic cardiomyopathy (Table 2 supplementary material), in line with the suggestions 
of the position statement of the European Society of Cardiology.w12 
The characteristics of the studies are detailed in Table 2. The reports covered a wide 
spectrum of DCM patients, with mean LVEF that ranged from 20% to 43%. The majority of 
studies evaluated the presence or absence of LGE by visual analysis.4,6,7,10,13-20,22,24-29,30,32  
Duration of follow-up ranged from 1 year to 5.3 years; mean follow up was 3 years. The 
majority of reports considered a composite arrhythmic end-point formed by sudden cardiac 
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death and/or aborted cardiac arrest, sustained ventricular arrhythmias and/or appropriate ICD 
therapies.4,5,7,8,10,13,14,16-18,20,22,25,28-31 
In two reports history of arrhythmic events was the end-point analyzed.9,32 These data 
were not used to calculate annual event rates, but were included in the evaluation of pooled 
OR. However, pooled OR were also calculated without the inclusion of these two reports. 
Additional data about arrhythmic events and/or LGE status were obtained for several 
studies by contacting the authors of the study.5,6,10,13-24,26-29 
Data synthesis: LGE and ventricular arrhythmias 
LGE was present in a variable proportion of patients with DCM (21% to 70%) and, 
overall, 1305 patients (44%) had LGE. The clinical characteristics of patients with and 
without LGE, when available, are presented (table 3 supplementary material).  
The arrhythmic endpoint occurred in 350 patients (12%), 272 of them with LGE (21% 
of LGE+ patients) and 78 without LGE (4.7% of LGE- patients), with a weighted risk 
difference between LGE+ and LGE- patients of 14.4% (95% CI 9.6%-19.2%, p<0.001). 
Annual event rate was 6.9% and 1.6% respectively in patients with and without LGE 
(weighted rate difference 4%, 95% CI 2.6%-5.5%, p<0.001). The presence of LGE was 
associated with significantly higher occurrence of the arrhythmic endpoint (pooled OR 4.3, 
p<0.001) (Table 3 and Figure 2).   
Heterogeneity was not significant (p=0.18) and inconsistency was low (19%); by 
consequence, the fixed-effect model yielded very similar results to the random-effect model 
(table 4, supplementary material). Egger and Peters test suggested the absence of publication 
bias, both including all studies and taking into account only those reports whose entire 
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population was used for the metaanalysis (Table 4). After exclusion of the two reports that 
analyzed history of arrhythmic events, the pooled OR remained 4.3. 
Metaregression analysis showed that neither the quality of the reports (Adjusted R2 -
0.03, p=0.26) nor the mean LVEF of each study (Adjusted R2 -0.04, p=0.52) had any 
significant impact over inter-study variability.  
Sub-group analysis 
The significant association between LGE and VA or SCD was maintained in both 
prospective and retrospective studies, in studies that performed visual analysis of LGE as 
well as in reports that used threshold-based methods to detect it. (Table 5)    
Among studies that reported a mean LVEF > 35%, the arrhythmic endpoint occurred 
in 23.9% of patients with LGE and 5.6% of patients without LGE and the annual event rate 
was 7.3% and 1.6%, respectively (p<0.001 for weighted risk and rate difference, Figure 3). In 
studies with a mean LVEF<35%, the arrhythmic endpoint occurred in 19.6% and 4.1% of 
patients and the annual event rate was 6.7% and 1.6%, respectively in patients with and 
without LGE (p<0.001 for weighted risk and rate difference). A significant association 
between LGE and VA or SCD was observed both when the mean LVEF was <35% (OR 4.2, 
95% CI 2.4-7.2) and when it was > 35% (OR 5.2, 95% CI 3.4-7.9) (Table 5).   
Considering studies that included only patients with primary prevention ICD, LGE 
was present in 42% of patients, the mean follow-up was 2 years, the overall incidence of the 
arrhythmic event was 17.1% and the overall annual event rate was 8.4%. The incidence of the 
arrhythmic endpoint was 34% vs 4.5% (p=0.004) and the annual rate was 17.2% vs 2.1% 
(p=0.007), respectively in patients with and without LGE. In this group of patients LGE had 
the highest OR for the arrhythmic endpoint (OR 7.8, 95% CI 1.7-35.8, p=0.008).  
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Analysis adjusting for confounding covariates 
Potential confounding covariates for the association between LGE and the arrhythmic 
endpoint were analyzed in four studies with a large population (n=946).4,17,25,30  The pooled 
adjusted hazard ratio (HR 6.7, 95% CI 3.6-12.5) indicates that LGE is an independent 
predictor of the arrhythmic endpoint (table 5, supplementary material).  
To further assess the potential role of LVEF as a confounding covariate, we estimated 
pooled OR in both studies where the LVEF did and did not significantly differ between 
patients with and without LGE. The significant association between LGE and VA or SCD 
was maintained in both groups of studies (Table 5).   
LVEF in relation to LGE and to the arrhythmic endpoint 
No significant correlation was identified between the proportion of patients with LGE 
and the mean LVEF in each study (r=-0.23, 95% CI -0.55 to +0.15, p=0.22). 
Mean LVEF did not correlate with the overall proportion of arrhythmic events 
(r=0.02, p=0.9) or the overall annual event rate from each study (r=0.07, p=0.7).  
When studies with mean LVEF > 35% or < 35% where considered separately, there 
was no significant difference between them in terms of overall percentages of arrhythmic 
events (12.2% vs 11.7%, p=0.7) or annual event rate (3.5% vs 4.2%, p=0.1) 
Discussion 
This metaanalysis, based on 2948 patients enrolled in 29 studies, represents the first 
systematic review that specifically evaluates the association between LGE and ventricular 
arrhythmias or sudden death among patients with DCM. The results clearly show that LGE is 
a robust predictor of VA or SCD across a wide spectrum of DCM patients.  
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Prior studies 
Two metaanalyses have evaluated the prognostic value of LGE in patients with 
DCM.w13,w14 However, in these two reports arrhythmic events were a secondary endpoint and, 
therefore, were not the main focus of the analyses. A significant association with LGE was 
found, but this result was based on fewer studies as compared with the current metaanalysis 
(7 and 12 studies, respectively). Moreover, detailed sub-group analysis or confounders-
adjusted analysis were not performed with regard to the arrhythmic endpoint. Finally, some 
differences in study inclusion are present (table 6, supplementary material).  
Given the wealth of studies published in the last two years and the absence of a 
metaanalysis that specifically focused on the arrhythmic endpoint in DCM, we considered 
that the current work was appropriate and necessary. 
The present report significantly strengthens and clarifies the evidence available up to 
date about the association between LGE and VA or SCD in patients with DCM. Thanks also 
to the collaboration of many authors of primary studies, it was possible to include a great 
number of reports and, from each study, to analyze only the population that precisely fitted 
the inclusion criteria of the metaanalysis. The specific focus on the arrhythmic outcome and 
the relevant number of studies included allowed a thorough sub-group analysis that 
contributed greatly to the relevance of this work.  
LGE and ventricular arrhythmias: a strong, consistent and independent 
association.  
LGE was present in a considerable proportion of patients with DCM (44%) and it had 
a strong and significant association with the arrhythmic endpoint. This association was 
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consistently observed across studies that included patients at different stages of their 
cardiomyopathy, and was independent of potential confounders at sub-group analysis.   
LGE could therefore add strong prognostic information across the entire spectrum of 
DCM patients.  
The differences in the mean LVEF reported by each study did not influence the 
association between LGE and the arrhythmic end-point. Mean LVEF did not correlate with 
the proportion of patients with LGE from each study and did not correlate at all with the 
overall proportion of arrhythmic events in each study. These data confirm that LVEF is not 
the optimal predictor of arrhythmic events in DCM and suggest that the prognostic value of 
LGE is superior and independent from LVEF.  
Potential clinical implications 
The present observations may have important clinical implications and may help 
addressing two major unresolved issues. 
Most of sudden deaths occur in patients without a severely impaired LVEF,w15 that are 
usually not protected by an ICD since they fall outside current indications for a primary 
prevention device.  
The association between LGE and with arrhythmic was present in studies with mean 
LVEF <35% but was even stronger when mean LVEF was >35%. Moreover, patients with 
LGE had a similar proportion of the arrhythmic endpoint in studies with a mean LVEF <35% 
and >35%. One may speculate if primary prevention ICD might be beneficial in patients with 
LGE, independently from their LVEF.  
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However, it must be underscored that none of the studies from this metaanalysis 
focused solely on patients with mild or moderate systolic impairment, excluding patients with 
severely reduced LVEF; therefore specific analysis just of patients with LVEF >35% was not 
possible. This is a key aspect that should be addressed by future studies.  
The second important clinical issue is the low rate of appropriate ICD therapies 
among patients with DCM that receive a primary prevention ICDw2 and the absence of 
survival benefit from primary prevention ICD in a contemporary cohort of patients with non 
ischemic cardiomyopathy, as outlined by the recently published DANISH trial.w3 This trial 
pointed out that patients with non ischemic cardiomyopathy implanted with a primary 
prevention ICD have a low arrhythmic risk; an improved risk stratification for sudden death 
is therefore urgently needed, to select only those patients that could benefit most from ICD.  
In this metaanalysis, LGE had the strongest association with the arrhythmic outcome 
(OR 7.8) among studies that included only patients with primary prevention ICD. Patients 
with LGE had a relatively high annual event rate (17.2%) while patients without LGE, who 
represented 58% of the population included in primary prevention ICD studies, had a 
considerably low event rate (2.1% per year). Therefore, incorporating LGE status into the 
selection criteria for primary prevention ICD might allow treating a sub-group of patients at 
higher arrhythmic risk (LGE-positive), while sparing patients without LGE the risk of 
complications from a device that is unlikely to improve their prognosis.   
Further large registries would be useful to confirm current data and randomized trials 
would be necessary to evaluate the impact of preventive ICD on mortality in patients with 
DCM without LGE.  
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In addition, recent evidence suggests that the absence of LGE is a predictor of left 
ventricular remodeling after cardiac resynchronization therapy (CRT).w16 Given the baseline 
low arrhythmic event rate in patient without LGE, and the lower rate of arrhythmic events 
observed in responders to CRT,w17 a sensible approach to patients without LGE and with no 
history of ventricular arrhythmias that need a CRT device could be to implant them with a 
pacemaker and not defibrillator; such a strategy should be evaluated in future studies.  
Possible substrates for ventricular arrhythmias in the presence or absence of LGE.  
The association between LGE and ventricular arrhythmias can be explained by the 
key role of myocardial scar as the main substrate for reentrant ventricular arrhythmias in 
patients with structural heart disease.w3 
However, a small proportion of patients without LGE still experienced the arrhythmic 
endpoint. Diffuse fibrosis is commonly found in DCM patients and it can be quantified by T1 
mapping. Such abnormality can alter the electrical properties of the myocardium and it might 
be especially important as a substrate for ventricular fibrillation (VF); as such, it could 
complement the information provided by LGE, which in one study was found to have 
stronger association with VT than VF.31   Further studies using T1 mapping and extracellular 
volume fraction (ECV) should address this issue. Indeed, T1 mapping and ECV has been 
associated with worse outcome in DCM.29,w18 
Limitations 
The main limitation of the present metaanalysis is the inclusion of observational 
studies, which all share an intrinsic risk of selection bias and can detect associations but not 
causality. However, it must be underscored that no randomized trials are available on this 
theme.  
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Precise data about ICD programming were not provided in the majority of the articles, 
and ICD settings significantly influence the rate of appropriate therapies.w19 
Most of the studies used visual analysis to detect the presence or absence of LGE 
while a minority of the reports used threshold based methods. It is important to stress that, 
regardless this disparity, no significant heterogeneity was observed across studies. Moreover, 
when analyzed separately, both studies that used visual analysis and threshold-based methods 
found a significant association between LGE and VA or SCD.  
Patients with DCM may have different patterns and variable extension of LGE and 
these factors might influence the arrhythmic risk. However, very few studies evaluated the 
association between LGE pattern25,30 or extension4,9,17,25,31 and arrhythmic events specifically 
in DCM. The limited data available and the differences in methods used not only to measure 
but also to report the quantification of LGE make these factors less suitable to be the target of 
a metaanalysis at present. 
The main result is a pooled non-adjusted odds ratio. However, pooled data from 
studies that had performed multivariate analysis confirmed that LGE is an independent 
predictor of VA.  
Conclusions 
Across a wide spectrum of patients with DCM, the presence of LGE is associated with 
an important and significant increase in the occurrence of ventricular arrhythmias or sudden 
death. The association between LGE and the arrhythmic outcome was independent from 
other covariates, including LVEF. LGE could therefore be a powerful tool to improve risk 
stratification in DCM.  
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The present findings raise two major issues that should be addressed in further 
studies: whether patients with LGE could benefit from primary prevention ICD irrespective 
of their LVEF and whether patients without LGE might not need a preventive ICD despite 
having severe left ventricular dysfunction.  
Perspectives 
Competency in medical knowledge 
The presence of late gadolinium enhancement at cardiac magnetic resonance is associated 
with a significant and relevant increase in the risk of ventricular arrhythmias or sudden 
cardiac death in patients with dilated cardiomyopathy.  
Translational outlook 1 
Further studies, especially randomized controlled trials, should evaluate whether patients with 
dilated cardiomyopathy and late gadolinium enhancement could benefit from a primary 
prevention ICD regardless of their left ventricular ejection fraction. 
Translational outlook 2 
Further studies, especially randomized controlled trials, should assess if patients with dilated 
cardiomyopathy and severe left ventricular dysfunction but without late gadolinium 
enhancement actually derive a survival benefit from primary prevention ICD. 
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Figure 1. Selection process of the studies included in the metaanalysis 
Figure 2. Forest plot of Odds Ratio. LGE, late gadolinium enhancement; VA, ventricular 
arrhythmias, SCD, sudden cardiac death. 
Figure 3. Annual rate of the arrhythmic endpoint according to LGE status. 
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Table 1. Quality assessment using Cochrane method 
 
 
 Selectio
n bias 
Performan
ce bias 
Attritio
n bias 
Detectio
n bias 
Reporting 
bias 
Wu Yes No No No No 
Yokokawa  Yes No NA No No 
Kono  Yes No Yes No No 
Looi  Yes No No No No 
Iles  Yes No No No No 
Fernandez Armenta  Yes No No No No 
Klem  Yes No No No No 
Leyva  Yes No No No No 
Masci 2012 Yes No No No No 
Gulati Yes No No No No 
Muller  Yes No No No No 
Neilan  Yes No No No No 
Sramko  Yes No No No No 
Yoshida  Yes No Yes No No 
Almehmadi  Yes No No No No 
Hasselberg  Yes No Yes No No 
Machii Yes No Yes No No 
Masci 2014 Yes No No No No 
Mordi  Yes No No No No 
25 
 
Nabeta  Yes No Yes No No 
Perazzolo Marra  Yes No No No No 
Rodriguez Capitan Yes No No No No 
Yamada  Yes No No No No 
Amzulescu Yes No No No No 
Barison  Yes No No No No 
Chimura  Yes No No No No 
Buss Yes No No No No 
Piers Yes No No No No 
Tachi Yes No NA No No 
 
NA, non applicable. 
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Table 2. Description of the studies included in the metaanalysis.  
 
Study Type of 
study 
Patients 
No. 
Population 
considered 
for 
metaanalysis 
Mea
n 
Age 
Mea
n 
LVE
F 
(%) 
LGE 
+ 
Method for 
evaluation of 
LGE 
Median 
follow 
up 
Arrhythmi
c 
endpoints 
evaluated 
Wu  
2008 
Prospective 
cohort, 
consecutive 
pts. 
65 DCM 
Primary 
prevention 
ICD 
55 24 24 
(42%) 
Visual analysis 17 
months 
SCD, ICD 
therapies 
Yokoka
wa  2009 
Cohort of 
consecutive 
pts 
29* DCM 
Admitted for 
HF, CRT or 
VT 
65 24 18 
(62%) 
Intensity >6SD 
of normal 
myocardium 
- VT 
Kono 
2010 
Observationa
l cohort study 
32 DCM 
LVEF<40% 
61 28 18 
(56%) 
Intensity > 2 SD 
normal 
myocardium 
31 
months 
(mean) 
SCD, VT, 
VF 
Looi 
2010 
 
Prospective 
cohort 
103 DCM 58 32 31 
(30%) 
Visual analysis 660 
days 
(mean) 
SCD, VA 
Iles 2011 Prospective 
cohort 
61* DCM 
Primary 
prevention 
54 25 31 
(52%) 
Intensity > 2 SD 
of normal 
myocardium 
573 
daysy 
ICD 
therapies 
27 
 
ICD 
Fdez-
Armenta 
2012 
Prospective 
cohort, 
consecutive 
pts. 
37* DCM, primary 
prevention 
CRT-D 
64 22 15 
(41%) 
Intensity > 2 SD 
of normal 
myocardium 
25 
monthsy 
ICD 
therapies 
Klem 
2012 
Prospective 
study 
64* DCM 52 41 37 
(58%) 
Visual analysis 24
monthsy 
SCD, ICD 
therapies 
Leyva 
2012 
Observationa
l cohort 
97* DCM with 
CRT 
66 22 20 
(21%) 
Visual analysis 1038 
daysy 
SCD, 
secondary 
prevention 
CRT-D 
Masci 
2012 
Prospective 
cohort 
125 DCM, 
LVEF<50%, 
NYHA I-II 
58 34 50 
(40%) 
Visual analysis 14 
months 
SCD 
Gulati 
2013 
Prospective 
cohort, 
consecutive 
pts. 
472 DCM 
Absence of 
subendocardia
l LGE 
51 37 142 
(30%) 
 
Visual analysis 5.3 
years 
SCD, ICD 
therapies, 
VF or VT 
Muller 
2013 
Observationa
l cohort 
167* Recent onset 
HF, DCM 
including 
myocarditis 
51y 43y 85 
(51%) 
Visual analysis 21 
monthsy 
rCA, VT, 
ICD 
therapies.  
Neilan 
2013 
Prospective 
cohort, 
162 DCM 
Primary 
55 26 81 
(50%) 
Visual analysis 26 
months 
SCD,  ICD 
therapies 
28 
 
consecutive 
pts.  
prevention 
ICD 
Sramko 
2013 
Cohort of 
consecutive 
pts. 
42 DCM, LVEF 
<45%, HF 
symptoms < 6 
months 
44 22 28 
(67%) 
Visual analysis 25 
months 
SCD, VT, 
ICD 
therapies 
Yoshida 
2013 
Retrospective 
cohort of 
consecutive 
pts.  
50 DCM, LVEF 
<45% 
57 25 21 
(42%) 
Visual analysis 33 
months 
VT, ICD 
therapies 
Almehm
adi 2014 
Cohort of 
consecutive 
pts. 
169* DCM, LVEF 
≤55% 
62y 33y 107 
(63%) 
Intensity >5 SD 
of normal 
myocardium 
467 
daysy 
SCA, ICD 
therapies 
Hasselbe
rg 2014 
Cohort of 
consecutive 
pt.  
13* DCM, 
mutations in 
lamin A/C 
52 32 4 
(31%) 
Visual analysis 29 
months 
y 
SCD, VT, 
ICD 
therapies 
Machii 
2014 
Retrospective 
cohort, 
multicenter 
72* DCM, 
LVEF<45% 
64 25 48 
(67%) 
Intensity > 3 SD 
of normal 
myocardium 
36 
months 
(mean) y 
SCD, VT 
Masci 
2014 
Prospective 
cohort, 
consecutive 
pts. 
228 DCM, no 
history of HF 
50 43 61 
(28%) 
Visual analysis 23 
months 
SCD, VT, 
VF, ICD 
therapies 
Mordi Prospective 96* DCM, primary 46 27 24 Intensity >5SD 915 ICD 
29 
 
2014 cohort, 
consecutive 
pts 
prevention 
ICD 
(25%) of normal 
myocardium 
days therapies 
Nabeta 
2014 
Observationa
l cohort 
75 DCM, 
LVEF<45% 
56 30 36 
(48%) 
Visual analysis 326 
days 
Sustained 
ventricular 
arrhythmia
s 
Perazzol
o Marra 
2014 
Cohort of 
consecutive 
pts.  
137 DCM, LVEF 
<50% 
49 36 76 
(55%) 
Visual analysis 3 years SCD, VT, 
VF, ICD 
therapies 
Rodrigue
z Capitan 
2014 
Retrospective 
cohort of 
consecutive 
pts.  
18* DCM 56y 29y 23 
(36%) 
Visual analysis 32  
monthsy 
ICD 
therapies 
Yamada 
2014 
Cohort of 
consecutive 
pts.  
57 DCM, LVEF 
<50% 
55 33 25 
(44%) 
Visual analysis 71 
months 
VT, VF 
Amzules
cu 2015 
Prospective 
cohort, 
consecutive 
pts. 
162 DCM, 
LVEF<40% 
55 25 63 
(39%) 
Visual analysis 3.4 
years 
SCD, VT, 
VF, ICD 
therapies 
Barison 
2015 
Prospective 
cohort 
89 DCM 59 41 39 
(44%) 
Visual analysis 24 
months 
SCD, 
sustained 
VA 
30 
 
Buss 
2015 
Prospective 
cohort, 
consecutive 
pts.  
23* DCM, LVEF 
≤ 50%, 
NYHA ≤III, 
ICD implanted
52y 36y 12 
(52%) 
Visual analysis 5.3 
yearsy 
ICD 
therapies 
 
Chimura 
2015 
Retrospective 
study 
175 DCM, LVEF 
<35%, NYHA 
II-III 
60 29 122 
(70%) 
Visual analysis 5.1 
years 
(mean) 
SCD, VT, 
VF, ICD 
therapies 
Piers 
2015 
Cohort of 
consecutive 
pts 
87 DCM 
Primary or 
secondary 
prevention 
ICD 
56 29 55 
(63%) 
≥35% of 
maximal 
myocardial 
signal intensity 
45 
months 
ICD 
therapies, 
aborted 
SCD 
Tachi 
2015 
Cohort of 
consecutive 
pts.  
41 DCM 60 20 21 
(51%) 
Visual analysis - VT 
CRT, cardiac resinchronization therapy; DCM, dilated cardiomyopathy; HF, heart failure; ICD, implantable cardioverter 
defibrillator; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; rCA, resuscitated cardiac arrest;  
SCD, sudden cardiac death; SD, standard deviation; VA, ventricular arrhythmias; VF, ventricular fibrillation; VT, 
ventricular rachycardia; * The population considered for this metaanalysis is a part of the total population of the original 
study. y Data derived from the entire population of the original study. 
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Table 3. Results of data synthesis. 
Study 
LGE+     
Events       No 
events 
LGE-    
Events       No 
events 
Weight  
(%) 
OR 
(95% CI) 
Wu 4 23 3 35 3.3 2 (0.4-9.9) 
Yokokawa 12 6      0   11 0.3 169.8        
Kono 4 14 2 12 2.4 1.7 (0.3-
Looi 6 25 1 71 1.8 17 (2-148.6) 
Iles  9   22  0   30 0.4 71.6         
Fernandez 7 8      0   22 0.5 78.4         
Klem 9 28 2 25 3.1 4 (0.8-20.4) 
Leyva  3 17  0   77 0.9 33.3         
Masci 2012 0 50  1   74 1 0.9 (0.1-
Gulati 42 100 23 307 26.7 5.6 (3.2-9.8) 
Muller 18 67 6 76 8.6 3.4 (1.3-9.1) 
Neilan 38 43 3 78 5.4 23 (6.7-
Sramko  3   25  0   14 0.2 20.7        
Yoshida 1 20  0   29 0.4 10.3         
Almehmadi 16 91 6 56 8.3 1.6 (0.6-4.4) 
Hasselberg 2 2      0   9   0.6 27.5         
Machii 2 46  0   24 0.2 14.5        
Masci 2014 6 55 2 165 3.1 9 (1.8-45.9) 
Mordi 3 21 5 67 3.6 1.9 (0.4-8.7) 
Nabeta 2 34  0   39 0.4 15.9         
Perazzolo 17 59 5 56 7.3 3.2 (1.1-9.3) 
32 
 
Rodriguez 0 8 2 8 1.1 0.3 (0.02-
Yamada 1 24  0   32 0.4 10.2         
Amzulescu 6 57 6 93 5.9 1.6 (0.5-5.3) 
Barison 5 34 2 48 2.9 3.5 (0.6-
Buss 9 3 3 8 2.4 8 (1.2-51.5) 
Chimura 18 104 0   53 0.2 105.8        
Piers 23 32 5 27 6.9 3.9 (1.3-
Tachi 6 15 1 19 1.7 7.6 (0.8-
Total 272 1033 78 1565 100 4.3 (3.3-5.8) 
For studies with a zero, the empirical correction for zeroes was applied and  the 
corrected raw data are presented in brackets. Weighted overall OR was 
calculated with the fixed effects model. 
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Table 4. Analysis of publication bias.  
 All studies (p) Studies whose entire 
population was included 
in metaanalysis (p) 
Egger’s method 0.13 0.49 
Peters’ method 0.43 0.56 
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Table 5. Sub-group analysis  
 
Type of study or 
population 
OR        
(95% CI) 
p Number 
of 
patients 
Number 
of 
studies 
Prospective studies 
4.2 (2.5-7.1)
<0.00
1 
1970 14 
Retrospective or non 
specified 
4.1 (2.4-7.1)
<0.00
1 
978 15 
Visual analysis of LGE 
4.9 (3.3-7.3)
<0.00
1 
2383 21 
Threshold-based LGE 
detection 
3.4 (1.6-7.7) 0.002 591 8 
Mean LVEF<35% 
4.2 (2.4-7.2)
<0.00
1 
1892 22 
Mean LVEF>35% 
5.2 (3.4-7.9)
<0.00
1 
1056 7 
ICD primary prevention 7.8 (1.7-
35.8) 
0.008 421 5 
LVEF not different between 6 (3.3-10.9) <0.00 1156 12 
35 
 
LGE+ and LGE- 1 
LVEF significantly  
different between LGE+ 
and LGE- 
5 (3.1-7.9) 
<0.00
1 
861 4 
ICD, implantable cardioverter defibrillator; LGE, late gadolinium enhancement; LVEF, 
 left ventricular ejection fraction.  
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Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2660     citations screened 
2553 excluded based on title and 
abstract 
54 excluded based on the type of 
article (reviews, guidelines, 
consensus statements) 
29  studies included in the 
metaanalysis 
24 excluded after full text 
analysis ± failed attempt 
to contact the author 
3 excluded because a more recent 
series from the same center was 
available  
7 excluded because specific data for 
the DCM sub-group were not 
available 
14 excluded because arrhythmic 
events were not reported separately 
or not segmented depending on the 
LGE status 
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Figure 2.  
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Figure 3.  
 
 
 
 
 
 
 
 
 
 
